## min read

TMS vs Ketamine and Spravato for Treatment-Resistant Depression

|

October 5, 2026

Summarize with AI

TMS vs Ketamine and Spravato for Treatment-Resistant Depression

If you are comparing TMS, ketamine, and Spravato for depression, you have probably reached the point where standard antidepressants have not done enough. All three are evidence-based options for treatment-resistant depression, and beyond that they have little in common. TMS is a course of magnetic stimulation delivered while you sit awake in a chair. Ketamine is an anesthetic given by IV, used off-label for depression. Spravato is a nasal spray made from esketamine, one of the two mirror-image forms that make up ketamine, with its own FDA approval and its own rulebook.

‍

None of the three is universally better. They differ in mechanism, speed, setting, and monitoring, and the right one depends on your clinical history and how you respond. Treatment-resistant depression generally means depression that has not adequately improved after at least two antidepressants taken at a proper dose for long enough, and that is the group where all three are most often used.

What Is TMS?

Transcranial magnetic stimulation uses a coil placed against the scalp to deliver focused magnetic pulses to the left dorsolateral prefrontal cortex, a region involved in mood regulation. The FDA first cleared TMS for major depressive disorder in 2008, according to the National Institute of Mental Health. It is delivered in an office, with no anesthesia and no medication.

‍

Our standard TMS course runs 20 to 30 daily sessions over four to six weeks, each 30 to 40 minutes long. You stay awake throughout and drive yourself home afterward. In real-world outcome data from 42 U.S. practices, more than half of patients with medication-resistant depression responded to a standard course, and more than a third reached remission.

What Is Ketamine Therapy?

Ketamine has been an FDA-approved anesthetic since 1970. Its use for depression is off-label: prescribed for a purpose the FDA has not formally approved, which is legal and common in medicine but leaves the safeguards less standardized. It is usually given as an IV infusion in a monitored clinic, as a series of sessions over a few weeks.

‍

Ketamine blocks the NMDA receptor, a glutamate receptor, rather than acting on serotonin like standard antidepressants, and that difference is thought to explain its speed. In a landmark 2006 trial, 18 people with treatment-resistant depression received a single infusion of 0.5 mg/kg, and their symptoms improved significantly within 110 minutes. By the next day, 71% had responded and 29% were in remission. One week later, 35% still met the response threshold. Rapid, real, and often short-lived.

‍

The catch is in the monitoring. Ketamine causes dissociation, a sense of detachment from your body or surroundings, plus sedation and blood pressure rises during and after the infusion, so you are observed until those effects pass and cannot drive that day. In a 2017 consensus statement in JAMA Psychiatry, an American Psychiatric Association task force found the evidence for rapid antidepressant effects convincing but the studies small, the longer-term efficacy data lacking, and the safety data on repeated dosing limited.

What Is Spravato (Esketamine)?

Ketamine is a mixture of two mirror-image molecules. Spravato is esketamine, one of those two, delivered as a nasal spray. Unlike IV ketamine, it has FDA approval for depression. The original approval came in March 2019 for treatment-resistant depression alongside an oral antidepressant, a second indication followed for adults with major depressive disorder and acute suicidal thoughts or behavior, and in January 2025 the FDA approved Spravato as a standalone monotherapy for treatment-resistant depression, with no oral antidepressant required, per the current prescribing information.

‍

That approval comes with a rulebook. Spravato can only be given at a setting certified under a Risk Evaluation and Mitigation Strategy (REMS) program: you take the spray under supervision, you are monitored for at least two hours before an assessment clears you to leave, and you cannot drive until the next day after a restful sleep. Its label carries a boxed warning for sedation, dissociation, respiratory depression, abuse and misuse, and suicidal thoughts and behaviors in younger patients.

‍

So is Spravato the same as ketamine? Related, not identical: same molecular family, same receptor, similar rapid onset and dissociative effects, but a different route, a formal FDA indication, and mandatory monitoring rules that off-label ketamine does not carry. For most people comparing TMS vs Spravato, those rules and insurance coverage are the practical differences that matter.

TMS vs Ketamine vs Spravato: Side-by-Side Comparison

Feature TMS IV ketamine Spravato (esketamine)
Mechanism Magnetic pulses stimulate the prefrontal cortex NMDA receptor antagonist, given intravenously NMDA receptor antagonist, nasal spray
FDA status Cleared for MDD (2008) and OCD (2018) Approved as an anesthetic; off-label for depression Approved for TRD (2019 with an oral antidepressant; 2025 as monotherapy) and for MDD with acute suicidal ideation
Onset Gradual, across a multi-week course Hours to days Hours to days
Session format 30 to 40 minutes, awake, in an office Infusion in a monitored clinic Self-administered spray under supervision in a certified setting
Monitoring None after the session Observed during and after the infusion At least two hours after each dose
Driving Drive yourself home Not that day Not until the next day
Typical course 20 to 30 daily sessions over 4 to 6 weeks A series of infusions over several weeks, then maintenance as needed Twice a week for the first four weeks, then weekly, with later dosing individualized
Common side effects Scalp discomfort, headache Dissociation, sedation, blood pressure rise, nausea Dissociation, dizziness, nausea, sedation, vertigo, raised blood pressure

Onset and Duration of Effect

Speed is the clearest dividing line. TMS builds gradually, and many people do not notice a clear change until the second or third week or later. Ketamine and Spravato can shift symptoms within hours to days.

‍

Speed and staying power are different things. Ketamine's effect after a single infusion often fades within a week or two, which is why it is given as a series with maintenance dosing. Spravato starts at twice a week and tapers, with the need for continued treatment reassessed along the way. Research on durability is still developing for all three, and none should be described as permanent.

Side Effects and Safety Considerations

TMS side effects are local and short-lived: scalp discomfort where the coil sits, headache, and sometimes brief lightheadedness or facial muscle twitching during the pulses. These usually settle within the first week, and because nothing enters the bloodstream there is no weight gain, sexual dysfunction, or sedation. Seizure is the one serious risk, exceedingly rare, and TMS is not used in people with a seizure history, metal in the head, or implanted electronic devices.

‍

Ketamine and Spravato share a different profile. The most common reactions to Spravato in trials were dissociation, dizziness, nausea, sedation, vertigo, numbness, anxiety, lethargy, increased blood pressure, vomiting, feeling drunk, and headache. Those effects peak in the hours after dosing, which is what the monitoring window is for, and both drugs carry a potential for misuse that shapes who is a candidate. Each option has its own screening, and a contraindication to one does not rule out the others.

Cost and Insurance

For TMS, most commercial insurers cover treatment for major depressive disorder once eligibility criteria are met, typically a confirmed diagnosis and documented antidepressant trials without adequate relief. Prior authorization is standard. For TMS we take all commercial insurance plans, cash pay is available, and authorization is something our intake team manages for you.

‍

Spravato is more commonly covered than off-label ketamine because it has an FDA indication insurers can write criteria around, though prior authorization and documentation of failed antidepressant trials are typically required. Ketamine infusion coverage varies widely, and many clinics are self-pay. Published cost estimates vary so much by dose, frequency, and insurance status that a single dollar figure would mislead; ask each provider and your insurer directly.

Can These Treatments Be Combined?

Sometimes, and the research is early. A 2024 systematic review found six published studies on combining TMS with ketamine, mostly case reports plus one retrospective review and one small pilot, and reported substantial and sustained improvement with generally mild side effects. The authors also said the designs were too varied and the samples too small for firm conclusions, and called for randomized trials.

‍

In practice, TMS and Spravato are sometimes used one after the other. Combining any of these is a clinical judgment a psychiatrist makes from your history, not a general recommendation, and the more common pattern is to use one, assess the response, then decide.

Choosing Between Them: What Influences the Decision

A psychiatrist weighing these options usually works through a short list:

‍

  • Treatment history. Which antidepressants, at what doses, for how long, and whether psychotherapy has been tried.
  • How urgently relief is needed. When symptoms are severe or suicidal thoughts are present, a faster-acting option may take priority, alongside care for suicidal thoughts.
  • Tolerance for the experience. Dissociation and a two-hour monitored window, versus a daily half-hour appointment for several weeks with no drug effects.
  • Practical constraints. Whether you can get to daily sessions, whether someone can drive you home after Spravato or ketamine, and what your insurance will authorize.
  • Health factors. Seizure history, metal implants, blood pressure, and any history of substance misuse each rule options in or out.
  • What else is in place. Any of the three works better inside ongoing psychiatric care and therapy than as a standalone fix.

Making the Decision With an Integrated Care Team

TMS, ketamine, and Spravato are tools, and tools do their best work inside a plan: a psychiatrist who knows your history, a therapist working alongside the biological treatment, and a team that notices when the plan needs to change.

‍

That is how we work. At Amae, our one-team care model combines psychiatry, therapy, primary care, and peer support, and TMS and Spravato are available through our Los Angeles and Bay Area clinics as part of that care. If you have been through the antidepressant cycle and want a clear, unhurried look at what comes next, talk with an Amae psychiatrist about your options. If you are in crisis or thinking about suicide, call or text 988 now.

Frequently Asked Questions

What is the difference between TMS and ketamine for depression?

TMS stimulates the brain with magnetic pulses over a course of daily outpatient sessions, with no drug, no sedation, and no monitoring afterward. Ketamine is a medication that acts on NMDA receptors, given by infusion or, as esketamine, by nasal spray, with monitored sedation and dissociation and often faster but shorter-lived effects.

Is Spravato the same as ketamine?

Related but not identical. Spravato is esketamine, the S-enantiomer of the ketamine molecule, delivered as an FDA-approved nasal spray under a required monitoring program. Ketamine infusions use the full ketamine compound and are prescribed off-label for depression, without an FDA indication for that use.

Is Spravato only approved with an antidepressant?

Not anymore. The original 2019 approval was for use alongside an oral antidepressant, and in January 2025 the FDA also approved Spravato as a standalone monotherapy for adults with treatment-resistant depression. Whether it is used alone or with an antidepressant is a decision your psychiatrist makes based on your situation.

Which works faster, TMS or Spravato?

Spravato. Esketamine and ketamine can produce symptom change within hours to days, while TMS builds gradually across a four-to-six-week course. Faster onset does not mean more durable improvement, and both durability and side effects belong in the comparison.

Can TMS and Spravato be used together?

Sometimes, as a clinical decision made with a psychiatrist based on your individual history. Both can be part of a broader treatment-resistant depression plan alongside medication and therapy, and the evidence on combining them is still early.

Is ketamine or Spravato covered by insurance?

Spravato is more commonly covered, because it has an FDA indication insurers can build criteria around, though prior authorization and proof of failed antidepressant trials are usually required. Coverage for off-label ketamine infusions varies widely and is often self-pay. Confirm with the provider and your insurer before starting.

‍

Citations

  1. National Institute of Mental Health. Brain Stimulation Therapies. https://www.nimh.nih.gov/health/topics/brain-stimulation-therapies/brain-stimulation-therapies
  2. Carpenter LL, Janicak PG, Aaronson ST, et al. Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. Depression and Anxiety. 2012. https://pubmed.ncbi.nlm.nih.gov/22689344/
  3. Zarate CA, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry. 2006. https://pubmed.ncbi.nlm.nih.gov/16894061/
  4. Sanacora G, Frye MA, McDonald W, et al. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry. 2017. https://pubmed.ncbi.nlm.nih.gov/28249076/
  5. U.S. Food and Drug Administration. Drugs@FDA: SPRAVATO (esketamine), NDA 211243, approval history. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211243
  6. U.S. Food and Drug Administration. SPRAVATO (esketamine) nasal spray prescribing information, revised January 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s016lbl.pdf
  7. Arubuolawe OO, Folorunsho IL, Busari AK, et al. Combination of transcranial magnetic stimulation and ketamine in treatment-resistant depression: a systematic review. Cureus. 2024. https://pubmed.ncbi.nlm.nih.gov/39156335/
  8. 988 Suicide and Crisis Lifeline. https://988lifeline.org

‍

Reccomended for you

# min read

What Is Metabolic Psychiatry and How Does It Work?

By

Sonia Garcia

|

September 25, 2026

Metabolic psychiatry is an emerging field that examines how metabolic dysfunction (insulin resistance, mitochondrial problems, and chronic inflammation) affects brain function.Rather than treating symptoms alone, it looks at the metabolic factors that may underlie conditions such as depression, bipolar disorder, and schizophrenia. The interest is strongest in complex mental illness, where standard treatment often falls short and where physical and psychiatric problems tend to travel together. This article explains the science behind the field, the therapies it uses, the evidence so far, and who researchers think it may help, along with the honest limits of what is still an early area of study.

What Is Metabolic Psychiatry?

Metabolic psychiatry views serious mental illnesses not solely as chemical imbalances or psychological phenomena, but as conditions also connected to disruptions in brain energy metabolism, inflammation, and cellular health. It does not discard the standard understanding of psychiatric illness. It adds a layer, asking whether the way the brain produces and uses energy is part of the picture.

‍

The term was introduced in 2015 by Dr. Shebani Sethi, who founded the first academic metabolic psychiatry clinic and research program at Stanford University after noticing how often her patients with treatment-resistant psychiatric conditions also had metabolic problems. The approach builds on more than a century of ketogenic-therapy research in neurology, where the ketogenic diet has long been used to treat drug-resistant epilepsy. Metabolic psychiatry is still emerging, and reputable clinicians frame it as a promising area of research rather than a finished or proven model of care.

The Link Between Metabolism and Mental Health

The brain is an energy-hungry organ. It makes up about 2% of body weight but uses roughly 20% of the body's energy, and it depends on a steady fuel supply to function. When metabolism breaks down, through insulin resistance, unstable blood sugar, or chronic inflammation, the brain can struggle to access the energy it needs, and researchers believe this may contribute to psychiatric symptoms.

‍

The connection runs in both directions. Roughly a third of people with schizophrenia or bipolar disorder also have metabolic syndrome, a cluster of conditions including high blood sugar, high blood pressure, and abnormal cholesterol (Vancampfort et al., World Psychiatry, 2015). People living with serious mental illness carry roughly 1.5 to 2 times the risk of metabolic syndrome and type 2 diabetes compared with the general population, an elevation driven partly by the illness, partly by medication side effects, and partly by shared biology. This is an association, not proven causation. But it is strong and consistent enough that the field takes it seriously.

How Does Metabolic Psychiatry Work?

The central idea, articulated most fully in Dr. Chris Palmer's Brain Energy theory, is that many mental disorders may be, in part, metabolic disorders of the brain. Palmer, a psychiatrist at McLean Hospital and Harvard Medical School, places mitochondria, the structures that produce energy inside cells, at the center of the model.

‍

Here is the mechanism in plain terms. When brain cells cannot get or use energy properly, often because insulin resistance blocks glucose from entering cells, it can trigger a cascade: mitochondrial dysfunction, oxidative stress, and inflammation. That cascade can disrupt neurotransmitters and interfere with the brain regions that regulate mood, thinking, and perception. Metabolic therapies aim to work upstream of that cascade, restoring the brain's energy supply and lowering inflammation rather than only adjusting neurotransmitters downstream. The theory is compelling and biologically plausible, and it remains a theory under active investigation, not settled fact.

Metabolic Therapies Used in Metabolic Psychiatry

One point clinicians in this field stress is that the toolkit is broader than a single diet. Metabolic health is shaped by many inputs, and a metabolic approach typically addresses several at once:

‍

  • Ketogenic therapy: the clinically supervised use of a well-formulated ketogenic diet to shift the brain toward ketones as fuel (the cornerstone intervention, covered below).
  • Nutritional changes: reducing sugar, ultra-processed foods, and refined carbohydrates.
  • Intermittent fasting: may improve insulin sensitivity and reduce inflammation.
  • Exercise: improves insulin sensitivity, supports mitochondrial function, and reduces inflammation.
  • Sleep optimization: poor sleep worsens insulin resistance and mitochondrial function.
  • Stress management: chronic stress raises cortisol, which disrupts glucose regulation.
  • Removing metabolic stressors: reducing smoking, excess alcohol, and sedentary time.

‍

Several of these are ordinary lifestyle measures. What is different in metabolic psychiatry is the reason behind them: they are used deliberately to improve brain energy metabolism, tracked with lab data, and coordinated with conventional psychiatric care.

Ketogenic Therapy: The Cornerstone Intervention

The ketogenic diet was developed more than a century ago to treat drug-resistant epilepsy, and that long neurological track record is part of why it draws the most research attention in psychiatry. A ketogenic diet is very low in carbohydrates, which shifts the body into nutritional ketosis: the liver begins converting fat into ketones, an alternate fuel the brain can use when insulin resistance limits its access to glucose.

‍

Beyond supplying fuel, ketones may reduce inflammation, lower oxidative stress, support mitochondrial function, and help rebalance neurotransmitters. Those are plausible mechanisms, and they are still being studied.

‍

The most important thing to understand is that ketogenic therapy, as used in this field, is a clinical intervention, not a do-it-yourself diet. It is supervised by clinicians, monitored with regular lab work, and integrated with a person's other treatment. It is not presented by responsible practitioners as a cure, and it is not a replacement for medication. Any change to psychiatric medication belongs in the hands of a treating clinician who knows the person's history.

What Does a Metabolic Psychiatry Evaluation Involve?

A metabolic approach usually starts with screening that goes beyond a standard psychiatric assessment, adding blood work to build a picture of a person's metabolic health. That panel commonly includes:

‍

  • Fasting glucose and insulin, plus hemoglobin A1C, to assess blood sugar regulation
  • A lipid panel: triglycerides, HDL, and LDL
  • A thyroid panel
  • Inflammatory markers such as C-reactive protein (CRP)
  • Key vitamin and mineral levels, including B12, folate, magnesium, and omega-3s

‍

The point of this data is not to produce a standalone diagnosis. It is to identify metabolic factors a clinician can address alongside conventional psychiatric care, and to establish a baseline that lab work can track over time.

Metabolic Psychiatry vs. Standard Psychiatry

Metabolic psychiatry is best understood as a complement to standard psychiatric care, not a replacement for it.

‍

Aspect Standard psychiatry Metabolic psychiatry
Assessment Primarily symptom-based Adds metabolic data (labs, biomarkers)
Focus Neurotransmitters and symptoms Brain energy, inflammation, and metabolism
Core tools Medication and therapy Metabolic optimization alongside conventional care
Best framed as Foundational, first-line care A complementary, root-cause layer

‍

The honest framing matters. Standard psychiatry, medication and therapy, remains the evidence-based foundation. Metabolic psychiatry adds a layer that some clinicians and researchers believe addresses root-cause biology, and it works best woven into conventional treatment rather than substituted for it.

How Metabolic Psychiatry Fits Within Precision Psychiatry

Metabolic psychiatry is often considered part of the broader precision psychiatry movement, which tailors treatment to each person's unique biology rather than applying population averages. Both reject one-size-fits-all, trial-and-error prescribing in favor of care informed by an individual's own data. Metabolic screening is one example of that data. Precision psychiatry is the larger shift, and it is the philosophy behind research programs like the Amae Institute, which studies how to match people living with complex conditions to more effective, individualized care.

Who Might Benefit from Metabolic Psychiatry?

Research and clinical interest are concentrated in complex mental health conditions, the situations where standard treatment most often falls short. The strongest focus so far has been on:

‍

  • Bipolar disorder and schizophrenia, where metabolic syndrome is common and where the first clinical trials have concentrated. People navigating a recent diagnosis can learn more about bipolar disorder treatment and how it is managed within an integrated model.
  • Treatment-resistant depression, where conventional approaches have not produced adequate relief.
  • People with co-occurring metabolic conditions such as insulin resistance, type 2 diabetes, or obesity.
  • People who have not responded well to, or cannot tolerate, standard treatments.

‍

Two caveats belong with every one of these. The field is emerging, so the evidence is still being built. And metabolic therapies are used alongside, not instead of, conventional psychiatric care, always under medical supervision. Whether a metabolic approach is appropriate for any individual is a clinical judgment, made by a clinician who knows that person's full history.

The Evidence So Far

The evidence is a mix of a strong foundation and promising but early results. Ketogenic therapy has more than a century of established use in epilepsy, which gives the underlying biology real credibility. For psychiatric conditions specifically, the picture is younger.

‍

In 2024, a Stanford pilot trial led by Dr. Sethi followed more than 20 adults with bipolar disorder or schizophrenia who also had metabolic abnormalities through a four-month ketogenic intervention. It was the first U.S. clinical trial of a ketogenic diet for serious mental illness since 1965. Most participants showed improvement in their psychiatric symptoms, reduced medication-related weight gain, and better metabolic markers; by the study's end, none still met the criteria for metabolic syndrome (Sethi et al., Psychiatry Research, 2024). It was a small, single-arm pilot, not a randomized controlled trial, so the results are encouraging rather than definitive.

‍

Alongside trials like this, case series and clinical reports describe stabilized mood and, in some cases, reduced reliance on medication under supervision. Larger, more rigorous randomized trials are now underway (Nature Mental Health, 2026). The honest summary: a solid mechanistic foundation, genuinely promising early psychiatric results, and a field that still needs bigger and better-controlled studies before anyone can call it established.

A Whole-Person Approach at Amae Health

The logic underneath metabolic psychiatry, that physical and mental health are not separate systems, is the same logic behind integrated care. At Amae Health, primary care physicians and registered dietitians are part of the psychiatric care team, so physical health, nutrition, sleep, and metabolic comorbidities are treated alongside mental health rather than as an afterthought. That is not the same as offering a specific metabolic-psychiatry program, but it reflects the same whole-person, precision-oriented conviction: complex conditions deserve care that looks at the whole biology of a person.

‍

If you or someone you love is living with a complex mental health condition, our care model and resources for patients and families explain how integrated treatment works. To ask about care, reach out to our team.

‍

If you are in crisis or thinking about suicide, call or text the 988 Suicide and Crisis Lifeline at 988 for free, confidential support, available 24/7.

Frequently Asked Questions

What is metabolic psychiatry?

Metabolic psychiatry is an emerging field that addresses metabolic dysfunction, such as insulin resistance, mitochondrial problems, and inflammation, that may affect brain function and mental health. It targets underlying metabolic factors alongside, not instead of, conventional psychiatric care.

‍

How does metabolic psychiatry work?

The brain depends on a steady energy supply. When metabolism is disrupted, often through insulin resistance that keeps cells from using glucose, the brain can struggle to access fuel, which researchers believe may worsen psychiatric symptoms. Metabolic therapies aim to restore that brain energy and reduce inflammation, working upstream of the neurotransmitter changes that standard treatment targets.

‍

What is ketogenic therapy for mental health?

It is the clinically supervised use of a well-formulated ketogenic diet to shift the brain toward ketones as fuel. Originally developed for epilepsy, it is the most-studied metabolic therapy for serious mental illness. It is used under medical supervision with regular lab monitoring, not as a do-it-yourself diet.

‍

Is metabolic psychiatry evidence-based?

Ketogenic therapy has strong evidence in epilepsy. For psychiatric conditions, the evidence is emerging: promising pilot studies and the early stages of larger trials, but still preliminary. It is used alongside conventional care, not in place of it.

‍

Can metabolic psychiatry replace medication?

No. It is designed to complement conventional psychiatric care, not replace it. Some people reduce their reliance on medication under close medical supervision, but changing psychiatric medication should never be attempted alone.

‍

Who is metabolic psychiatry best for?

Research has focused most on bipolar disorder, schizophrenia, and treatment-resistant depression, especially alongside co-occurring metabolic conditions. A clinician who knows the person's history determines whether a metabolic approach is appropriate. Support is available, and no one should navigate a serious condition alone.

‍

Citations

  1. Vancampfort D, Stubbs B, Mitchell AJ, et al. "Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis." World Psychiatry, 2015. PubMed 26407790. Tier 1 (peer-reviewed meta-analysis).
  2. Sethi S, Wakeham D, Ketter T, et al. "Ketogenic Diet Intervention on Metabolic and Psychiatric Health in Bipolar and Schizophrenia: A Pilot Trial." Psychiatry Research, 2024. PubMed 38547601. Tier 1 (peer-reviewed pilot trial).
  3. "Metabolic psychiatry targeting metabolic dysregulation in mental health." Nature Mental Health, 2026. nature.com. Tier 1 (peer-reviewed review).

‍

Further reading (external resources): Stanford Metabolic Psychiatry (Dr. Shebani Sethi); Metabolic Mind (Baszucki Group).

‍

# min read

Schizophrenia vs Schizoaffective Disorder: Key Differences in Diagnosis and Treatment

By

Sonia Garcia

|

October 21, 2026

Schizophrenia vs schizoaffective disorder is one of the harder distinctions in psychiatry, and many families hear both terms before anyone settles on one. Both conditions involve psychosis: hallucinations, delusions, and disorganized thinking. The difference is mood. In schizoaffective disorder, major mood episodes (depression, mania, or both) occur alongside the psychosis and are present for most of the illness. In schizophrenia, psychosis is the core of the illness, and any major mood episodes fill only a minority of its course.

‍

That one difference decides how each diagnosis is made, why the label sometimes changes over time, and whether treatment targets psychosis alone or psychosis and mood together.

What Is Schizophrenia?

Schizophrenia affects how a person thinks, feels, and behaves. The National Institute of Mental Health groups its symptoms into three kinds:

‍

  • Psychotic symptoms: hallucinations, delusions, and thought disorder, meaning speech or reasoning that is hard to follow.
  • Negative symptoms: loss of motivation, loss of interest or enjoyment in daily activities, and withdrawal from social life.
  • Cognitive symptoms: problems with attention, concentration, and memory.

‍

People are usually diagnosed between the ages of 16 and 30, after a first episode of psychosis. Under the DSM-5-TR, the American Psychiatric Association's diagnostic manual, the diagnosis requires at least two core symptoms, one of them hallucinations, delusions, or disorganized speech. Signs of the illness must persist for at least six months, with a marked decline in work, relationships, or self-care.

‍

Depression can occur in schizophrenia too. But what matters for the diagnosis is proportion: any major mood episodes that overlap with active psychosis account for only a minority of the illness's total duration.

‍

Psychosis itself is a symptom rather than a diagnosis, and our guide to psychosis vs. schizophrenia explains where one ends and the other begins. Researchers are still working out why schizophrenia develops, and our article on whether schizophrenia is genetic covers what's known about inherited risk.

What Is Schizoaffective Disorder?

Schizoaffective disorder combines the psychotic symptoms of schizophrenia with major mood episodes. MedlinePlus, the National Library of Medicine's health reference, describes it as causing both a loss of contact with reality and mood problems, and notes that it is thought to be less common than schizophrenia or mood disorders.

‍

A schizoaffective disorder diagnosis rests on three requirements in the DSM-5-TR:

‍

  1. A mood episode during psychosis. A major depressive or manic episode occurs at the same time as the core symptoms of schizophrenia.
  2. Psychosis on its own, too. At some point in the illness, delusions or hallucinations last two weeks or more with no major mood episode present. This is the criterion that separates schizoaffective disorder from a mood disorder with psychotic features, where psychosis appears only during mood episodes.
  3. Mood episodes for most of the illness. Symptoms meeting criteria for a major mood episode are present for the majority of the illness's total duration, counting both active and residual phases.

‍

Substance use and other medical conditions also have to be ruled out as the cause. Clinicians then specify a type. In the bipolar type, a manic episode is part of the picture, and major depressive episodes may occur as well. In the depressive type, only major depressive episodes occur.

Schizophrenia vs Schizoaffective Disorder: Key Diagnostic Differences

Feature Schizophrenia Schizoaffective disorder
Core symptoms Hallucinations, delusions, and disorganized thinking, plus negative and cognitive symptoms The same psychotic symptoms, plus major depressive or manic episodes
Role of mood episodes Absent, or present for only a minority of the illness's total duration Present for the majority of the illness's total duration
Psychosis without a mood episode Psychosis is the persistent core of the illness Required: at least two weeks of delusions or hallucinations with no mood episode
Duration rules Continuous signs for at least six months Mood episodes measured against the full course of the illness
Types No subtypes in current criteria Bipolar type and depressive type
Typical course Symptoms tend to persist between acute phases Often more up and down, following the mood episodes
Medication foundation Antipsychotic medication Antipsychotic medication, often with a mood stabilizer or antidepressant

Why Diagnosis Can Take Time

No blood test, brain scan, or single interview can settle the difference between schizophrenia and schizoaffective disorder. MedlinePlus is plain about it: there are no medical tests to diagnose schizoaffective disorder.

‍

The deciding criterion is also about proportion over time. To say that mood episodes have filled most of an illness, a clinician needs to see a good part of that illness, and early on there often isn't much history to see. Schizophrenia's own criteria require six months of continuous signs.

‍

Early presentations overlap, too. A first episode of psychosis with depression could turn out to be schizophrenia, schizoaffective disorder, bipolar disorder with psychotic features, or major depressive disorder with psychotic features. The questions that separate them take time to answer. Does the psychosis continue when mood is stable? For how long? How much of the illness has been dominated by mood episodes?

‍

The research shows how often the picture shifts. A 2016 meta-analysis of 31 rediagnosis studies in Bipolar Disorders found that 36% of people first diagnosed with schizoaffective disorder had a different diagnosis at a later assessment, most often schizophrenia (19%) or a mood disorder (14%). The shift ran the other way as well: 55% of people diagnosed with schizoaffective disorder at follow-up had started out with a different diagnosis.

‍

A revised diagnosis usually reflects a clearer view of the pattern, not a failure. Records from earlier treatment, observations from family members, and careful tracking of mood alongside psychotic symptoms all help a psychiatrist get there sooner.

Treatment Approaches for Each

For schizophrenia, antipsychotic medication is the foundation. NIMH explains that these medications can make psychotic symptoms less intense and less frequent; most are taken daily as a pill or liquid, and some are given as an injection once or twice a month. Medication works alongside psychosocial treatment, and NIMH lists cognitive behavioral therapy, behavioral skills training, supported employment, and cognitive remediation among the options. For early psychosis, coordinated specialty care brings psychotherapy, medication, case management, employment and education services, and family education and support into a single plan.

‍

Schizoaffective disorder treatment adds a second target: the mood episodes. MedlinePlus describes antipsychotic medicines for the psychotic symptoms, antidepressants or mood stabilizers for the mood symptoms, and talk therapy plus support with work and daily skills. Which mood medication is used depends on the pattern of episodes, particularly whether mania has been part of the illness.

‍

In both conditions, medication is one part of the plan, not the whole of it. For more depth, see what the best treatment for schizophrenia looks like, and our page on how we treat psychosis describes how our teams coordinate that care.

Course and Outlook

Neither label is a forecast. Both conditions vary widely from person to person.

‍

Because its mood episodes come and go, schizoaffective disorder often follows a more up-and-down course than schizophrenia, whose symptoms tend to be more continuous. MedlinePlus notes that people with schizoaffective disorder have a better chance of returning to their previous level of functioning than people with most other psychotic disorders. It also notes that long-term treatment is often needed.

‍

For both diagnoses, improvement is realistic, and it usually builds through steady treatment over time, with adjustments along the way, rather than arriving all at once.

Getting an Accurate Diagnosis and Care

Sorting out schizophrenia vs schizoaffective disorder is rarely a one-visit job. Getting it right shapes the whole treatment plan: it decides whether care targets psychosis alone or psychosis and mood together, and it gives families a clearer sense of what to watch for.

‍

Schizophrenia and schizoaffective disorder are among the conditions we specialize in at Amae. At our integrated outpatient clinics for adults 18 and older, the psychiatrist, therapist, primary care provider, and peer mentor work from one shared plan, so diagnosis, medication, and support stay coordinated instead of scattered across offices. If a diagnosis in your family still feels unsettled, talk with an Amae psychiatrist about diagnosis and care. In a crisis, the 988 Suicide and Crisis Lifeline answers by call or text, day or night.

Frequently Asked Questions

Is schizoaffective disorder more or less severe than schizophrenia?

Neither is simply more severe. They differ in pattern: schizoaffective disorder adds major mood episodes to psychosis. MedlinePlus notes that people with schizoaffective disorder have a better chance of returning to their previous level of functioning than people with most other psychotic disorders, but outcomes vary widely from person to person.

Can schizoaffective disorder turn into schizophrenia, or vice versa?

A diagnosis can change as a clinician sees more of the illness, particularly whether mood episodes keep occurring alongside psychosis. In one meta-analysis, about a third of schizoaffective diagnoses changed at reassessment, most often to schizophrenia. That reflects a clearer picture, not one condition becoming another.

How long does it take to get an accurate diagnosis?

Often several months. Schizophrenia requires at least six months of continuous signs, and schizoaffective disorder depends on how much of the whole illness has involved mood episodes, which takes time to observe. No single test gives an immediate answer.

Do schizophrenia and schizoaffective disorder need the same medications?

Both use antipsychotic medication as the foundation. Schizoaffective disorder usually adds a mood stabilizer or an antidepressant, depending largely on whether the mood episodes have included mania. The right combination is worked out individually with a psychiatrist.

Is schizoaffective disorder the same as bipolar disorder with psychotic features?

No. In bipolar disorder with psychotic features, psychosis happens only during mood episodes. Schizoaffective disorder requires at least two weeks of delusions or hallucinations with no mood episode present, a distinction written into the DSM-5-TR criteria.

Are schizophrenia and schizoaffective disorder treated at Amae Health?

Yes. Both are among the conditions we specialize in. We treat adults 18 and older through integrated outpatient care, where one team coordinates medication, therapy, physical health, and peer support.

‍

Citations

  1. National Institute of Mental Health. Schizophrenia. https://www.nimh.nih.gov/health/publications/schizophrenia
  2. MedlinePlus, U.S. National Library of Medicine. Schizoaffective disorder. https://medlineplus.gov/ency/article/000930.htm
  3. Santelmann H, Franklin J, Bußhoff J, Baethge C. Diagnostic shift in patients diagnosed with schizoaffective disorder: a systematic review and meta-analysis of rediagnosis studies. Bipolar Disorders. 2016;18(3):233-246. https://pubmed.ncbi.nlm.nih.gov/27226263/
  4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). 2022.
  5. 988 Suicide and Crisis Lifeline. https://988lifeline.org

‍

# min read

How Long Do TMS Results Last? Maintenance and Relapse

By

Sonia Garcia

|

October 10, 2026

Finishing a course of TMS and feeling like yourself again brings a new worry: will it hold? How long do TMS results last, and what happens if the depression comes back? The research is more encouraging than many people expect. Among people who respond to a course, roughly half to nearly two-thirds are still responding a year later, and when symptoms do return, restarting TMS brought back the improvement for most people in the research.

‍

None of that predicts any one person's course. It does show what tends to help results last, and why the months after treatment deserve a plan of their own.

What "Lasting" Means: Response vs. Remission

Two terms do most of the work in durability research. A person has responded when their depression scores fall by at least half on a standard rating scale. They're in remission when scores drop low enough that the depression is largely gone.

‍

Durability studies then ask a narrower question than the original trials did: of the people who responded or reached remission by the end of a course, how many were still doing well months later? That framing matters when you read the numbers. A result such as 62.5% of people keeping their response for a year describes people who had already responded, not everyone who started TMS. Those follow-up checks happen at set points, typically three, six, and 12 months after a course, so durability is reported as the share of people still responding at each checkpoint.

What the Research Shows About Durability

The most direct data come from a 2014 study in The Journal of Clinical Psychiatry that followed people with medication-resistant major depression for a year after they finished TMS at 42 U.S. clinical practices. Of the 257 people who completed a course and agreed to follow-up, 120 had responded or reached remission by the end of treatment. Of those 120, 75 (62.5%) kept meeting response criteria through the full 12 months.

‍

Two details shape that result. The study used a practical approach after the course: continued antidepressant medication, plus access to more TMS if symptoms returned. And over the year, 93 participants (36.2%) had TMS reintroduced at some point, averaging about 16 treatment days. So the 62.5% reflects TMS inside ongoing care, not a single course left to stand on its own.

‍

A 2019 meta-analysis in Brain Stimulation pooled 19 studies of people who had responded to a TMS course. About two-thirds were still responding at three months, about 53% at six months, and about 46% at one year. The authors' summary: roughly half of responders keep their response for up to a year after a successful course.

‍

Read together, the two studies give a realistic range of around half to nearly two-thirds of responders still doing well a year out. The other side of those numbers matters just as much. A meaningful share of people see symptoms return within the first year, and planning for that possibility is part of good care, not a sign that treatment failed.

Factors That Influence How Long Results Last

The research has identified a few patterns, mostly at the level of groups rather than individuals:

‍

  • Maintenance treatment. In the 2019 meta-analysis, studies that included maintenance treatment showed higher sustained response at some time points.
  • The mix of people studied. Studies with a higher proportion of women also showed higher sustained response, a group-level pattern that says nothing reliable about any one person.
  • Continued medication. The best-known durability results come from people who stayed on antidepressants after TMS, so those numbers describe that combination.
  • A completed course. Durability figures come from people who finished a full acute course. They don't describe what happens after a partial one.

‍

Clinicians also weigh a person's history when planning follow-up, such as how many depressive episodes they've had and how many treatments failed before TMS. The findings above don't establish how much those factors change the odds, so they inform a clinician's judgment rather than supply a number.

Maintenance TMS: What It Is and Who May Need It

TMS maintenance treatment means periodic sessions after the main course, scheduled to protect a response rather than to answer a relapse. Schedules vary between providers and between people, and no single schedule has become standard.

‍

The evidence supports the idea without settling the details. The 2019 meta-analysis found maintenance associated with more durable response, and its authors suggested maintenance be considered in practice and tested in future trials. That's a promising signal, not a proven protocol. Maintenance TMS is also separate from staying on medication: in both the year-long and six-month studies, people continued antidepressants whether or not they received more TMS.

‍

Not everyone needs it. Some people stay well for long stretches without it. Whether maintenance makes sense for a particular person is a judgment a psychiatrist makes from their history and how they're doing in the months after the course.

Can TMS Be Repeated If Symptoms Return?

Yes, and the research on restarting TMS is among the most reassuring parts of this topic. In a six-month study in Brain Stimulation, people whose depression had improved by at least a quarter with TMS stopped treatment gradually over three weeks while starting maintenance antidepressant medication. In that study, worsening had a specific meaning: a clinician-rated decline that held for two consecutive weeks, which triggered restarting TMS. Over the next 24 weeks, 38% had symptoms worsen enough to restart TMS, and 32 of those 38 people (84%) regained their improvement. Only 10% of the 99 people whose results were reported met the study's definition of relapse.

‍

A repeat course is different from maintenance. Maintenance is planned in advance to hold a response; a repeat course starts because symptoms have come back. In the year-long study described above, about a third of participants had TMS reintroduced at some point. Whether and when to restart is a decision made with a psychiatrist, based on how symptoms are changing.

What Helps Results Last Longer

Beyond maintenance and continued medication, two more things help, though neither promises that results will last for a particular person:

‍

  • Catching changes early. In the six-month study, regular assessments flagged worsening symptoms, and most people who restarted TMS at that point regained their improvement.
  • Staying connected to care. Therapy and regular psychiatric visits mean someone is watching for early changes between treatments.

‍

Knowing what returning depression tends to look like makes early changes easier to catch: shifts in sleep or appetite, lower energy, less interest in usual activities, and a low mood that lingers instead of lifting after a few days. When those signs show up, reaching out sooner gives a care team more options, and our guide on how to ask for help when depressed covers how to start that conversation.

‍

These describe what research associates with better long-term results in groups of patients. They aren't instructions for any one person's treatment plan; that's a psychiatrist's call, made with the whole history in view.

Talking to a Psychiatrist About a Long-Term Plan

A TMS course is the start of a plan, not the end of one. The months afterward are when follow-up, medication decisions, and a clear plan for what happens if symptoms return matter most.

‍

At Amae, TMS sits inside our integrated care model, where psychiatric care, therapy, primary care, and peer support stay linked after the course ends. We provide TMS therapy for major depressive disorder at our Los Angeles clinic and at our Bay Area clinics in Los Altos and San Mateo. Commercial insurance plans and cash pay are both accepted, and our intake team handles prior authorization. To map out what comes after a course, talk with an Amae psychiatrist about a long-term plan. Anyone in crisis can reach the 988 Suicide and Crisis Lifeline by call or text.

Frequently Asked Questions

How long do TMS results typically last?

For many people, months to a year or longer, though it varies. In a year-long study of people who responded to TMS, 62.5% kept meeting response criteria for the full 12 months. A 2019 meta-analysis found that about half of responders were still responding at one year.

What percentage of people relapse after TMS?

Some return of symptoms within a year is common. In the 2019 meta-analysis, roughly half of responders were no longer responding at one year. That isn't always a full relapse: in a six-month study, 38% had symptoms worsen enough to restart TMS, while 10% met the study's definition of relapse.

Can TMS be repeated if depression comes back?

Yes. In a six-month study, 84% of people whose symptoms worsened regained their improvement when TMS was restarted. A repeat course is different from ongoing maintenance sessions, and the decision is made with a psychiatrist based on individual history.

Do I need maintenance TMS sessions after my initial course?

Not necessarily. Some people stay well without them, and there is no standard maintenance schedule across providers. Research links maintenance with longer-lasting response, so whether it fits is a decision a psychiatrist makes based on your response and how closely symptoms are being monitored.

What can help TMS results last longer?

The research points to planned follow-up, continued medication when it's part of the plan, and catching symptom changes early. These are general findings from groups of patients, not instructions for any one person's treatment.

Is maintenance TMS covered by insurance?

It depends on the insurer and on whether sessions are billed as maintenance or as a new course for returning symptoms, since coverage can differ between the two. Ask the provider to verify benefits with your insurer before sessions begin.

‍

Citations

  1. Dunner DL, Aaronson ST, Sackeim HA, et al. A multisite, naturalistic, observational study of transcranial magnetic stimulation for patients with pharmacoresistant major depressive disorder: durability of benefit over a 1-year follow-up period. Journal of Clinical Psychiatry. 2014;75(12):1394-1401. https://pubmed.ncbi.nlm.nih.gov/25271871/
  2. Senova S, Cotovio G, Pascual-Leone A, Oliveira-Maia AJ. Durability of antidepressant response to repetitive transcranial magnetic stimulation: systematic review and meta-analysis. Brain Stimulation. 2019;12(1):119-128. https://pubmed.ncbi.nlm.nih.gov/30344109/
  3. Janicak PG, Nahas Z, Lisanby SH, et al. Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study. Brain Stimulation. 2010;3(4):187-199. https://pubmed.ncbi.nlm.nih.gov/20965447/
  4. 988 Suicide and Crisis Lifeline. https://988lifeline.org

‍